摘要
目的探讨长春瑞滨（NVB）加顺铂联合化疗治疗晚期非小细胞肺癌（NSCLC）的近期疗效及不良反应.方法34例应用长春瑞滨25mg/m^2,iv,第1、8天;顺铂40mg/d,ivgtt,第1～3天.结果CR1例,PR14例,SD14例,PD5例,有效率44.1%.主要不良反应为骨髓抑制、消化道反应及静脉炎.结论长春瑞滨加顺铂联合化疗方案治疗晚期非小细胞肺癌的疗效较高,不良反应可耐受,可作为一线化疗方案或二线补救方案.
Objective To evaluate the short term efficacy and adverse reaction of combination chemotherapy with vinorelbine plus eisplatin in the treatment of non-small- cell lung cancer （NSCLC）.
Methods Thirty- four patients with advanced NSCLC were treated with Vinorelbine 25 mg/m^2, iv,dl ,d8; （;isplatin 40mg/ d, ivgtt, d1-3. Results The overall response rate was 44, 1% with CR1 case and PR 14 eases. 14 cases was stable and 5 patients was progressive, The mainly adverse reactions were myelo- suppression, digestive tract reaction and vein inflammation. Conclusions The combination chemotherapy with vinorelbine and cisplatin is an active regimen with tolerable adverse reaction for advanced NSCLC, and can be adopt as first regimen or the supplement of second regimen.
出处
《实用全科医学》
2006年第2期178-179,共2页
Applied Journal Of General Practice
关键词
长春瑞滨
顺铂
联合化疗
非小细胞肺癌
Vinorelbine
Cisplatin
Combined chemotherapy
Non- small- cell lung cancer
